Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Ear­li­er Tues­day, End­points News re­port­ed that for­mer Stan­ford pres­i­dent Marc Tessier-Lav­i­gne will lead one of biotech’s biggest-ever start­up launch­es: Xaira Ther­a­peu­tics, which has se­cured over $1 bil­lion to trans­form drug dis­cov­ery and de­vel­op­ment with AI.

The move is sure to raise eye­brows. Tessier-Lav­i­gne re­signed from his post at Stan­ford last sum­mer af­ter an in­tense in­ves­ti­ga­tion found ev­i­dence of fal­si­fied da­ta in some of his old re­search pa­pers. Al­though Tessier-Lav­i­gne was cleared of wrong­do­ing him­self, the pan­el cri­tiqued his lab over­sight and said he was too slow to cor­rect or re­tract the bad da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER